Treace Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2024 Revenue
Treace Medical Concepts (NASDAQ: TMCI) has released preliminary, unaudited financial results for Q4 and full-year 2024. The company reported preliminary Q4 revenue between $68.4-68.8 million, representing approximately 10% growth compared to Q4 2023. Full-year 2024 preliminary revenue reached $209.0-209.4 million, showing roughly 12% growth year-over-year and aligning with previous guidance of $204-211 million.
The company added approximately 280 new active surgeons in 2024, ending the year with about 3,135 active surgeons, a 10% increase from 2023. This represents approximately 31% of the estimated 10,000 U.S. surgeons performing bunion surgery. The company plans to provide 2025 financial guidance during its Q4 2024 earnings call scheduled for February 27, 2025.
Treace Medical Concepts (NASDAQ: TMCI) ha pubblicato i risultati finanziari preliminari, non verificati, per il quarto trimestre e l'intero anno 2024. L'azienda ha riportato ricavi preliminari per il Q4 compresi tra 68,4 e 68,8 milioni di dollari, che rappresentano circa il 10% di crescita rispetto al Q4 2023. I ricavi preliminari per l'intero anno 2024 hanno raggiunto 209,0-209,4 milioni di dollari, mostrando una crescita annua di circa il 12% e allineandosi con le previsioni precedenti di 204-211 milioni di dollari.
L'azienda ha aggiunto circa 280 nuovi chirurghi attivi nel 2024, chiudendo l'anno con circa 3.135 chirurghi attivi, un aumento del 10% rispetto al 2023. Questo rappresenta circa il 31% dei circa 10.000 chirurghi statunitensi che effettuano interventi di chirurgia del piede. L'azienda prevede di fornire indicazioni finanziarie per il 2025 durante la chiamata sugli utili del Q4 2024, programmata per il 27 febbraio 2025.
Treace Medical Concepts (NASDAQ: TMCI) ha publicado los resultados financieros preliminares, no auditados, para el cuarto trimestre y el año completo 2024. La compañía reportó ingresos preliminares para el Q4 entre 68,4 y 68,8 millones de dólares, lo que representa aproximadamente un crecimiento del 10% en comparación con el Q4 2023. Los ingresos preliminares para el año completo 2024 alcanzaron 209,0-209,4 millones de dólares, mostrando un crecimiento de aproximadamente el 12% año tras año y alineándose con la orientación anterior de 204-211 millones de dólares.
La compañía añadió aproximadamente 280 nuevos cirujanos activos en 2024, cerrando el año con cerca de 3.135 cirujanos activos, un aumento del 10% respecto a 2023. Esto representa aproximadamente el 31% de los 10,000 cirujanos en EE. UU. que realizan cirugía de juanetes. La compañía planea proporcionar orientación financiera para 2025 durante su llamada de ganancias del Q4 2024, programada para el 27 de febrero de 2025.
Treace Medical Concepts (NASDAQ: TMCI)는 2024년 4분기 및 연간 예비 감사 없는 재무 결과를 발표했습니다. 회사는 2024년 4분기 매출이 6840만에서 6880만 달러 사이라고 보고했으며, 이는 2023년 4분기 대비 약 10% 성장한 수치입니다. 2024년 전체 연간 매출은 2억 900만에서 2억 940만 달러에 달해, 전년 대비 약 12% 성장했으며, 2억 400만에서 2억 110만 달러의 이전 지침과 일치합니다.
회사는 2024년에 약 280명의 신규 활성 외과의사를 추가하여 3,135명의 활성 외과의사로 연도를 마감했습니다. 이는 2023년 대비 10% 증가한 수치입니다. 이는 미국에서 약 10,000명의 외과의사가 시행하는 발목수술을 시행하는 외과의사의 약 31%에 해당합니다. 회사는 2024년 4분기 실적 발표에서 2025년 재무 지침을 제공할 예정이며, 이 회의는 2025년 2월 27일로 예정되어 있습니다.
Treace Medical Concepts (NASDAQ: TMCI) a publié des résultats financiers préliminaires, non audités, pour le quatrième trimestre et l'année entière 2024. L'entreprise a rapporté des revenus préliminaires pour le T4 compris entre 68,4 et 68,8 millions de dollars, ce qui représente une croissance d'environ 10 % par rapport au T4 2023. Les revenus préliminaires pour l'ensemble de l'année 2024 ont atteint 209,0-209,4 millions de dollars, soit une croissance d'environ 12 % par rapport à l'année précédente et conforme aux prévisions antérieures de 204-211 millions de dollars.
L'entreprise a ajouté environ 280 nouveaux chirurgiens actifs en 2024, clôturant l'année avec environ 3.135 chirurgiens actifs, une augmentation de 10 % par rapport à 2023. Cela représente environ 31 % des 10 000 chirurgiens américains estimés pratiquant la chirurgie du pied. L'entreprise prévoit de fournir des prévisions financières pour 2025 lors de son appel de résultats du T4 2024, prévu pour le 27 février 2025.
Treace Medical Concepts (NASDAQ: TMCI) hat vorläufige, untestierte Finanzzahlen für das 4. Quartal und das gesamte Jahr 2024 veröffentlicht. Das Unternehmen berichtete von vorläufigen Einnahmen im 4. Quartal zwischen 68,4 und 68,8 Millionen Dollar, was einem Wachstum von etwa 10% im Vergleich zum 4. Quartal 2023 entspricht. Die vorläufigen Einnahmen für das gesamte Jahr 2024 erreichten 209,0-209,4 Millionen Dollar, was einem jährlichen Wachstum von rund 12% entspricht und in Übereinstimmung mit der vorherigen Prognose von 204-211 Millionen Dollar liegt.
Das Unternehmen fügte im Jahr 2024 etwa 280 neue aktive Chirurgen hinzu und schloss das Jahr mit etwa 3.135 aktiven Chirurgen, was einem Anstieg von 10% gegenüber 2023 entspricht. Dies entspricht ungefähr 31% der geschätzten 10.000 U.S.-Chirurgen, die Fußoperationen durchführen. Das Unternehmen plant, während seiner Gewinnbekanntgabe für das 4. Quartal 2024, die für den 27. Februar 2025 angesetzt ist, eine Finanzprognose für 2025 bereitzustellen.
- Q4 2024 revenue grew ~10% year-over-year to $68.4-68.8 million
- Full-year 2024 revenue increased ~12% to $209.0-209.4 million
- Added 280 new active surgeons in 2024
- Total active surgeon base grew 10% to 3,135
- Achieved 31% penetration of estimated U.S. bunion surgeon market
- Revenue growth rate decelerated from previous periods
Insights
The preliminary Q4 and FY2024 results from Treace Medical show mixed signals. Revenue growth of
The expansion of active surgeons by
Looking at the competitive landscape, Treace's focus on bunion-specific technology and dedicated sales force provides differentiation, but the slowing growth rate may indicate market saturation or increased competition in the space. The upcoming product launches mentioned could be important for maintaining growth momentum, though their impact remains speculative until concrete details emerge.
The orthopedic device market dynamics revealed in Treace's preliminary results warrant careful analysis. The achievement of approximately 3,135 active surgeons represents a significant foothold in the bunion surgery market, but the pace of new surgeon adoption appears to be moderating. This suggests the company is approaching a critical phase where penetrating the remaining
The emphasis on "differentiated technologies" and "innovative product launches" signals a strategic pivot toward product portfolio expansion, which is essential in the medical device sector where product lifecycle management drives long-term success. However, the relatively modest revenue growth despite significant surgeon presence indicates potential challenges in procedure volume per surgeon or reimbursement optimization.
The timing of this announcement ahead of the J.P. Morgan Healthcare Conference suggests confidence in the company's strategic direction, though investors will likely seek more detail on the pipeline and growth acceleration strategies during the presentation. The market's response will largely depend on the specifics of the 2025 guidance to be provided in February.
PONTE VEDRA, Fla., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced its preliminary, unaudited fourth quarter and full-year 2024 results.
Highlights:
- Preliminary revenue of
$68.4 million to$68.8 million in the fourth quarter of 2024, an approximate10% increase at the midpoint over the same period in 2023. - Preliminary revenue of
$209.0 million to$209.4 million for the full-year 2024, an approximate12% increase at the midpoint compared to the prior year and in-line with the previously provided revenue guidance range of$204 million to$211 million . - New active surgeon additions of approximately 280 for full-year 2024; ended the year with approximately 3,135 active surgeons, a
10% increase compared to the prior year and approximately31% of the estimated 10,000 U.S. surgeons performing bunion surgery.
“We close 2024 with new product announcements and
2025 Outlook
Treace plans to provide 2025 financial guidance during its fourth quarter 2024 earnings conference call, which is currently scheduled for Thursday, February 27, 2025, at 4:30 p.m. Eastern Time.
The preliminary unaudited financial information in this press release has not been subject to the more rigorous standards of review for Treace’s filed financial statements, may be adjusted, including as a result of its internal closing processes and the external auditing procedures of its independent registered public accounting firm, and remains subject to change until the Company files its full financial statements for 2024.
Treace to Present at J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025
John T. Treace, Chief Executive Officer and Founder of Treace, will present at the J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, beginning at 9:00 am Pacific Time / 12:00 pm Eastern Time. Following this presentation, Mr. Treace will be joined by Mark L. Hair, Chief Financial Officer of Treace, for a question-and-answer session. A live webcast and replay of the presentation will be available on the Company’s investor relations website at https://investors.treace.com/.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements, including, but not limited to the Company’s anticipated fourth quarter and full-year 2024 revenue and 2024 active surgeons, as well as its belief that the Company is positioned for continued growth in 2025 and beyond and will further drive penetration into the overall bunion market and continue to expand its surgeon customer base through 2025 and beyond. Forward-looking statements are based on management’s current assumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Factors that could cause actual results or other events to differ materially from those contemplated in this press release can be found in the Risk Factors section of Treace’s public filings with the Securities and Exchange Commission (“SEC”), including its Annual Report on Form 10-K for the year ended December 31, 2023, and any subsequent Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of their date and, except to the extent required by law, the Company undertakes no obligation to update these statements, whether as a result of any new information, future developments or otherwise. The Company’s preliminary, unaudited results for the fourth quarter and full year ended December 31, 2024, reflect the Company’s current estimates based on information available as of the date of this press release and are subject to change, including as a result of the completion of the Company’s financial and operating closing procedures, customary audit procedures, and other developments that may occur before the completion of these procedures. Accordingly, you should not place undue reliance on these preliminary, unaudited results, which may differ materially from actual results and are not necessarily indicative of its operating results for any future periods.
Internet Posting of Information
Treace routinely posts information that may be important to investors in the “Investor Relations” section of its website at www.treace.com. The Company encourages investors and potential investors to consult the Treace website regularly for important information about Treace.
About Treace Medical Concepts
Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 67 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty® 3D Bunion Correction® System – a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. To further support the needs of bunion patients, Treace has introduced its Adductoplasty® Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities. The Company continues to expand its footprint in the foot and ankle market with the introduction of its SpeedPlate™ Rapid Compression Implants, an innovative fixation platform with broad versatility across Lapiplasty® and Adductoplasty® procedures, as well as other common bone fusion procedures of the foot. For more information, please visit www.treace.com.
To learn more about Treace, connect with us on LinkedIn, X, Facebook and Instagram.
Contacts:
Treace Medical Concepts
Mark L. Hair
Chief Financial Officer
mhair@treace.net
(904) 373-5940
Investors:
Gilmartin Group
Vivian Cervantes
IR@treace.net
FAQ
What was Treace Medical's (TMCI) revenue growth in Q4 2024?
How many active surgeons did TMCI add in 2024?
What was TMCI's market penetration among U.S. bunion surgeons in 2024?
When will TMCI announce its 2025 financial guidance?
Did TMCI meet its 2024 revenue guidance?
